Literature DB >> 23499462

Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

Magdalena A Kuszczyk1, Sandrine Sanchez, Joanna Pankiewicz, Jungsu Kim, Malgorzata Duszczyk, Maitea Guridi, Ayodeji A Asuni, Patrick M Sullivan, David M Holtzman, Martin J Sadowski.   

Abstract

Accumulation of β-amyloid (Aβ) in the brain is a key event in Alzheimer disease pathogenesis. Apolipoprotein (Apo) E is a lipid carrier protein secreted by astrocytes, which shows inherent affinity for Aβ and has been implicated in the receptor-mediated Aβ uptake by neurons. To characterize ApoE involvement in the intraneuronal Aβ accumulation and to investigate whether blocking the ApoE/Aβ interaction could reduce intraneuronal Aβ buildup, we used a noncontact neuronal-astrocytic co-culture system, where synthetic Aβ peptides were added into the media without or with cotreatment with Aβ12-28P, which is a nontoxic peptide antagonist of ApoE/Aβ binding. Compared with neurons cultured alone, intraneuronal Aβ content was significantly increased in neurons co-cultured with wild-type but not with ApoE knockout (KO) astrocytes. Neurons co-cultured with astrocytes also showed impaired intraneuronal degradation of Aβ, increased level of intraneuronal Aβ oligomers, and marked down-regulation of several synaptic proteins. Aβ12-28P treatment significantly reduced intraneuronal Aβ accumulation, including Aβ oligomer level, and inhibited loss of synaptic proteins. Furthermore, we showed significantly reduced intraneuronal Aβ accumulation in APPSW/PS1dE9/ApoE KO mice compared with APPSW/PS1dE9/ApoE targeted replacement mice that expressed various human ApoE isoforms. Data from our co-culture and in vivo experiments indicate an essential role of ApoE in the mechanism of intraneuronal Aβ accumulation and provide evidence that ApoE/Aβ binding antagonists can effectively prevent this process.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499462      PMCID: PMC3644726          DOI: 10.1016/j.ajpath.2013.01.034

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  59 in total

1.  Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice.

Authors:  Marlen Knobloch; Uwe Konietzko; Danielle C Krebs; Roger M Nitsch
Journal:  Neurobiol Aging       Date:  2006-07-31       Impact factor: 4.673

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

4.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

Authors:  K R Bales; T Verina; R C Dodel; Y Du; L Altstiel; M Bender; P Hyslop; E M Johnstone; S P Little; D J Cummins; P Piccardo; B Ghetti; S M Paul
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

Review 5.  Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.

Authors:  Gunnar K Gouras; Davide Tampellini; Reisuke H Takahashi; Estibaliz Capetillo-Zarate
Journal:  Acta Neuropathol       Date:  2010-03-31       Impact factor: 17.088

6.  Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.

Authors:  Robert M Koffie; Tadafumi Hashimoto; Hwan-Ching Tai; Kevin R Kay; Alberto Serrano-Pozo; Daniel Joyner; Steven Hou; Katherine J Kopeikina; Matthew P Frosch; Virginia M Lee; David M Holtzman; Bradley T Hyman; Tara L Spires-Jones
Journal:  Brain       Date:  2012-05-26       Impact factor: 13.501

7.  Rapid and direct detection of apolipoprotein E genotypes using whole blood from humans.

Authors:  Suhng Wook Kim; Ji Hye Heo; Chun Huem Kim; Dong Chul Yoo; Dong Hwan Won; Seung Gwan Lee; Kyoung Jin Cho; Jung Han Song; Su Jeong Park; Young Geun Yang; Dal Woong Choi
Journal:  J Toxicol Environ Health A       Date:  2010

8.  Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Authors:  Lauren M Billings; Salvatore Oddo; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

9.  Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease.

Authors:  H M Wisniewski; M Sadowski; K Jakubowska-Sadowska; M Tarnawski; J Wegiel
Journal:  J Neuropathol Exp Neurol       Date:  1998-07       Impact factor: 3.685

10.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

View more
  36 in total

1.  Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.

Authors:  Ayodeji A Asuni; Maitea Guridi; Joanna E Pankiewicz; Sandrine Sanchez; Martin J Sadowski
Journal:  Ann Neurol       Date:  2014-04-28       Impact factor: 10.422

2.  Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology.

Authors:  Shan Liu; Ariel Breitbart; Yanjie Sun; Pankaj D Mehta; Allal Boutajangout; Henrieta Scholtzova; Thomas Wisniewski
Journal:  J Neurochem       Date:  2013-11-06       Impact factor: 5.372

3.  Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Authors:  Tina Bilousova; Mikhail Melnik; Emily Miyoshi; Bianca L Gonzalez; Wayne W Poon; Harry V Vinters; Carol A Miller; Maria M Corrada; Claudia Kawas; Asa Hatami; Ricardo Albay; Charles Glabe; Karen H Gylys
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

Review 4.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 5.  Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.

Authors:  Sreedevi Raman; Nicholas Brookhouser; David A Brafman
Journal:  Neurobiol Dis       Date:  2020-02-05       Impact factor: 5.996

6.  Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.

Authors:  Eloise Hudry; Jonathan Dashkoff; Alysson D Roe; Shuko Takeda; Robert M Koffie; Tadafumi Hashimoto; Maria Scheel; Tara Spires-Jones; Michal Arbel-Ornath; Rebecca Betensky; Beverly L Davidson; Bradley T Hyman
Journal:  Sci Transl Med       Date:  2013-11-20       Impact factor: 17.956

7.  1MeTIQ provides protection against Aβ-induced reduction of surface expression of synaptic proteins and inhibits H₂O₂-induced oxidative stress in primary hippocampal neurons.

Authors:  Magdalena A Kuszczyk; Martin J Sadowski; Lucyna Antkiewicz-Michaluk; Jerzy W Lazarewicz
Journal:  Neurotox Res       Date:  2013-11-20       Impact factor: 3.911

8.  Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model.

Authors:  Wenjuan Zhao; Sonya B Dumanis; Irfan Y Tamboli; Gustavo A Rodriguez; Mary Jo Ladu; Charbel E H Moussa; G William Rebeck
Journal:  Hum Mol Genet       Date:  2013-10-23       Impact factor: 6.150

Review 9.  β-Amyloid peptides and amyloid plaques in Alzheimer's disease.

Authors:  Gunnar K Gouras; Tomas T Olsson; Oskar Hansson
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

10.  Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo.

Authors:  Ayodeji A Asuni; Maitea Guridi; Sandrine Sanchez; Martin J Sadowski
Journal:  Neurochem Int       Date:  2015-08-08       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.